Eddie Hickman
Stock Analyst at Guggenheim
(3.81)
# 858
Out of 4,996 analysts
17
Total ratings
62.5%
Success rate
9.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.97 | - | 4 | Aug 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $56.29 | +49.23% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.41 | +1,367.71% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.77 | +125.18% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $14.44 | +121.61% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $5.86 | +497.27% | 1 | Mar 13, 2025 |
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.97
Upside: -
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $56.29
Upside: +49.23%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.41
Upside: +1,367.71%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.77
Upside: +125.18%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $14.44
Upside: +121.61%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $5.86
Upside: +497.27%